23 This analysis revealed that the hazard ratios of patients treated with EGFR-blocking antibodies (cetuximab or panitumumab) were not depending on the BRAF mutation status for overall survival (interaction test P -value: 0.43) but were close to significance for progression-free survival (interaction test P -value: 0.07). 23 The authors concluded that the BRAF mutation was not predictive of benefits provided by anti-EGFR therapies.
1
—
—